During the last session, Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB)’s traded shares were 0.8 million, with the beta value of the company hitting -0.19. At the end of the trading day, the stock’s price was $1.52, reflecting an intraday gain of 32.17% or $0.37. The 52-week high for the CNTB share is $1.60, that puts it down -5.26 from that peak though still a striking 66.45% gain since the share price plummeted to a 52-week low of $0.51. The company’s market capitalization is $84.13M, and the average intraday trading volume over the past 10 days was 0.16 million shares, and the average trade volume was 130.87K shares over the past three months.
Connect Biopharma Holdings Ltd ADR (CNTB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CNTB has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.22.
Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) trade information
Connect Biopharma Holdings Ltd ADR (CNTB) registered a 32.17% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 32.17% in intraday trading to $1.52, hitting a weekly high. The stock’s 5-day price performance is 29.99%, and it has moved by 91.19% in 30 days. Based on these gigs, the overall price performance for the year is 10.14%. The short interest in Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) is 17062.0 shares and it means that shorts have 0.21 day(s) to cover.
The consensus price target of analysts on Wall Street is $1.5, which implies a decrease of -1.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.5 and $1.5 respectively. As a result, CNTB is trading at a premium of 1.32% off the target high and 1.32% off the low.
Connect Biopharma Holdings Ltd ADR (CNTB) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 7.77%. While earnings are projected to return -208.28% in 2025, the next five years will return -24.15% per annum.
CNTB Dividends
Connect Biopharma Holdings Ltd ADR is due to release its next quarterly earnings on 2023-Sep-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB)’s Major holders
Connect Biopharma Holdings Ltd ADR insiders own 40.65% of total outstanding shares while institutional holders control 43.97%, with the float percentage being 74.09%. BML CAPITAL MANAGEMENT, LLC is the largest shareholder of the company, while 17.0 institutions own stock in it. As of 2024-06-30, the company held over 2.04 million shares (or 3.7053% of all shares), a total value of $3.11 million in shares.
The next largest institutional holding, with 0.51 million shares, is of UBS OCONNOR LLC’s that is approximately 0.9261% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.78 million.
Data provided on May 31, 2025 indicates that Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund owns about 23.32 shares. This amounts to just over 0.04 percent of the company’s overall shares, with a $35446.0 market value.
